TY  - JOUR
AU  - Borrero-Palacios, A
AU  - Cebrián, A
AU  - Gómez Del Pulgar, M T
AU  - García-Carbonero, R
AU  - Garcia-Alfonso, P
AU  - Aranda, E
AU  - Elez, E
AU  - López-López, R
AU  - Cervantes, A
AU  - Valladares, M
AU  - Nadal, C
AU  - Viéitez, J M
AU  - Guillén-Ponce, C
AU  - Rodríguez, J
AU  - Hernández, I
AU  - García, J L
AU  - Vega-Bravo, R
AU  - Puime-Otin, A
AU  - Martínez-Useros, J
AU  - Del Puerto-Nevado, L
AU  - Rincón, R
AU  - Rodríguez-Remírez, M
AU  - Rojo, F
AU  - García-Foncillas, J
PY  - 2019
DO  - 10.1038/s41598-019-39291-2
UR  - http://hdl.handle.net/10668/13615
T2  - Scientific reports
AB  - Cetuximab is a standard-of-care treatment for RAS wild-type metastatic colorectal cancer (mCRC) but not for those harbor a KRAS mutation since MAPK pathway is constitutively activated. Nevertheless, cetuximab also exerts its effect by its...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Immunological
KW  - Biomarkers, Tumor
KW  - Cetuximab
KW  - Colorectal Neoplasms
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Genes, MCC
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Polymorphism, Genetic
KW  - Prospective Studies
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Receptors, IgG
KW  - Receptors, KIR
KW  - Treatment Outcome
TI  - Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
TY  - research article
VL  - 9
ER  -